Who
Nello Mainolfi
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Kymera Therapeutics.
In numbers
- Trades disclosed
- 224
- Buys
- 0
- Sells
- 36
- Bought
- $0
- Sold
- $75.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Aug 2020
- Last trade
- 1 Oct 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 1 Oct 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $62K30,000 at $2.08 | filing |
| 1 Oct 2026filed 1 Oct 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $393K3,525 at $111.44 | filing |
| 1 Oct 2026filed 1 Oct 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $619K5,506 at $112.42 | filing |
| 1 Oct 2026filed 1 Oct 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $552K4,876 at $113.24 | filing |
| 1 Oct 2026filed 1 Oct 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $870K7,601 at $114.43 | filing |
| 1 Oct 2026filed 1 Oct 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $950K8,230 at $115.40 | filing |
| 1 Oct 2026filed 1 Oct 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K262 at $116.12 | filing |
| 1 Oct 2026filed 1 Oct 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 7 Jul 2026filed 7 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $104K50,000 at $2.08 | filing |
| 7 Jul 2026filed 7 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $6.0M50,000 at $119.00 | filing |
| 7 Jul 2026filed 7 Jul 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —45,559 at $0.00 | filing |
| 7 Jul 2026filed 7 Jul 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —45,559 at $0.00 | filing |
| 7 Jul 2026filed 7 Jul 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,441 at $0.00 | filing |
| 7 Jul 2026filed 7 Jul 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,441 at $0.00 | filing |
| 7 Jul 2026filed 7 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $104K50,000 at $2.08 | filing |
| 7 Jul 2026filed 7 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $6.0M50,000 at $119.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $166K80,000 at $2.08 | filing |
| 1 Jul 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $212K1,883 at $112.80 | filing |
| 1 Jul 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $755K6,626 at $113.98 | filing |
| 1 Jul 2026filed 2 Jul 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —80,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.